Daniel J Lerner
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2020First federal award
$6.6MFederal grants as PI8 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
8 awards · $6.6M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 28, 2025 | NIH | SBIR Phase II Targeting LRRC8 signaling to prevent & treat arterial thrombosis in type 2 diabetes | $1.0M | Senseion Therapeutics, Inc. |
| Sep 19, 2024 | NIH | SBIR Phase II Targeting LRRC8 signaling to prevent & treat arterial thrombosis in type 2 diabetes | $982K | Senseion Therapeutics, Inc. |
| Aug 30, 2023 | NIH | SBIR Phase II Targeting LRRC8 signaling to prevent & treat arterial thrombosis in type 2 diabetes | $323K | Senseion Therapeutics, Inc. |
| Aug 26, 2022 | NIH | SBIR Phase II Optimizing SWELL1 modulators to treat non-alcoholic steatohepatitis | $1.1M | Senseion Therapeutics, Inc. |
| Aug 25, 2022 | NIH | SBIR Phase II Targeting SWELL1 Signaling to Treat Obesity-Induced Type 2 Diabetes | $991K | Senseion Therapeutics, Inc. |
| Sep 17, 2021 | NIH | SBIR Phase II Targeting SWELL1 Signaling to Treat Obesity-Induced Type 2 Diabetes | $993K | Senseion Therapeutics, Inc. |
| Aug 3, 2021 | NIH | SBIR Phase II Optimizing SWELL1 modulators to treat non-alcoholic steatohepatitis | $946K | Senseion Therapeutics, Inc. |
| Sep 15, 2020 | NIH | SBIR Phase II Optimizing SWELL1 modulators to treat non-alcoholic steatohepatitis | $301K | Senseion Therapeutics, Inc. |
Peer ranks
Federal funding#155
Awards as PI#190
Patents#273
Companies
- Senseion Therapeutics, Inc.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.